| Negative VEGF intensity (0–1) | Positive VEGF intensity (2–3) |  | ||
---|---|---|---|---|---|
(n = 48) | (n = 55) | ||||
Characteristics | n | % | n | % | p-value* |
Age | |||||
 Median | 71.5 |  | 71 |  |  |
 Range | 55 – 77 |  | 55 – 81 |  |  |
 <71 | 21 | 44 | 27 | 49 | 0.588* |
 ≥71 | 27 | 56 | 28 | 51 |  |
Assigned Treatment | |||||
 STAD + RT arm | 22 | 46 | 23 | 42 | 0.682 |
 RT alone arm | 26 | 54 | 32 | 58 |  |
Combined Gleason Score | |||||
 Missing | 0 | 0 | 1 | 2 |  |
 2-6 | 14 | 29 | 11 | 20 | 0.303** |
 7-10 | 34 | 71 | 43 | 78 |  |
Clinical Stage | |||||
 T2 | 14 | 29 | 12 | 22 | 0.392* |
 T3 | 34 | 71 | 43 | 78 |  |
Failures | |||||
 Overall Survival | 39 | 81 | 51 | 93 |  |
 Distant Metastasis | 25 | 52 | 31 | 56 |  |
 Local Progression | 21 | 44 | 26 | 47 |  |
 Disease-free Survival | 48 | 100 | 54 | 98 |  |
 Biochemical Failure | 37 | 77 | 40 | 73 |  |